1967年Cox合成了第一个抑制过敏反应介质释放的药物色甘酸钠(FPL 670,1),1于1969年应用于临床,首先证实了其对过敏性哮喘的预防作用,俟后又逐步发现它对过敏性鼻炎、荨麻疹、溃疡性结肠炎等过敏性疾病有可喜的效果。其软膏外用于慢性湿疹、某些皮肤瘙痒症也有显著疗效。因此,色甘酸钠的研制成功是抗过敏药物研究的一个重大突破。缺点是色甘酸钠口服极少吸收,用 In 1967 Cox synthesized the first drug, cromolyn (FPL 670,1), which inhibits the release of anaphylactic-responsive mediators, which was first introduced in clinical practice in 1969 and first demonstrated its prophylactic effect on allergic asthma and later on It allergic rhinitis, urticaria, ulcerative colitis and other allergic diseases have encouraging results. Its ointment for chronic eczema, some pruritus also have a significant effect. Therefore, the successful development of cromolyn is a major breakthrough in anti-allergic drug research. The disadvantage is cromolyn sodium oral absorption, use